2-[3-[4-[1-[(3-fluorophenyl)methyl]indol-4-yl]piperazin-1-yl]propoxy]benzamide | 1416970-62-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-[3-[4-[1-[(3-fluorophenyl)methyl]indol-4-yl]piperazin-1-yl]propoxy]benzamide
• 英文别名: 2-(3-(4-(1-(3-fluorobenzyl)-1H-indol-4-yl)piperazin-1-yl)propoxy)benzamide；2-[3-[4-[1-[(3-Fluorophenyl)methyl]indol-4-yl]piperazin-1-yl]propoxy]benzamide
• CAS: 1416970-62-1
• 化学式: C₂₉H₃₁FN₄O₂
• 分子量: 486.589
• InChiKey: VVKLFXHTLGCGNU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  36
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  63.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-(1H-4-吲哚)-哌嗪-1-羧酸叔丁酯 在 盐酸 、 18-冠醚-6 、 potassium tert-butylate 、 三乙胺 、 potassium iodide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙腈 为溶剂， 反应 8.66h， 生成 2-[3-[4-[1-[(3-fluorophenyl)methyl]indol-4-yl]piperazin-1-yl]propoxy]benzamide
  参考文献：
  名称：

  Effects of chronic mild stress on rats selectively bred for behavior related to bipolar disorder and depression

  摘要：

  To test the possibility that chronic mild stress (CMS) might be unreliable in producing its often-intended outcome (i.e., decreased preference for sucrose, hypothesized to represent depression-relevant anhedonia) because it is typically applied to "normal" rats, a CMS procedure was applied to rats that may possess genetic susceptibility to affective disorders, having had been selectively-bred to show behavior indicative of such disorders. These rat lines were: Hyperactive (HYPER) rats, which show characteristics of bipolar disorder, Swim-test Susceptible (SUS) and Swim-test Resistant (RES) rats, being susceptible or resistant to effects of stress in the swim test, Swim High-active (SwHi) and Swim Low-active (SwLo) rats, which innately show high or low activity in the swim test These selectively-bred lines were compared to normal, non-selectively bred (NS) rats. During CMS, HYPER rats, both females and males, as well as RES and SwHi rats, showed reduced consumption of a palatable 2% sucrose solution, and reduced preference for sucrose (vs. water) in comparison to non-stressed rats (no CMS) of the same lines. In contrast, CMS produced no decrease in sucrose consumption or in preference for sucrose in normal NS rats, and actually a caused a slight increase in sucrose consumption and preference in male NS rats. Other measures that indicate depression - food intake and motor activity in the home cage - were also assessed. SwLo and SwHi showed greater sensitivity to having their home-cage ambulatory activity reduced by CMS than did NS rats, but no other such differences relative to NS rats were seen for these other measures; thus, changes in sucrose intake or preference could not be explained by a change in caloric intake. These results suggest that the genetic attributes of animals can influence the outcome of CMS, and that the application of CMS to normal, non-selected rats may account, at least in part, for the unreliability of CMS in decreasing consumption of palatable substances and decreasing preference for such substances. (C) 2013 Published by Elsevier Inc.

  DOI：

  10.1016/j.physbeh.2013.05.042

文献信息

• INDOLEAMINE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES
  申请人：Kolaczkowski Marcin

  公开号：US20140121216A1

  公开（公告）日：2014-05-01

  Indoleamine derivatives of formula (IA), R 1 represents benzyl unsubstituted or substituted with halogen atom, —OH, or C 1 -C 3 -alkyl; phenylsulphonyl unsubstituted or substituted in the phenyl ring with halogen atom, —OH or C 1 -C 3 -alkyl; G 1 represents phenoxyalkyl, heteroaryloxyalkyl- or heterocyclyloxyalkyl-piperazine moiety; and pharmaceutically acceptable salts and solvates thereof. The compounds may be useful for the treatment and/or prevention of the central nervous system disorders.

  公式（IA）的吲哚胺衍生物，其中R1代表苄基未取代或取代为卤原子，-OH，或C1-C3-烷基；苯磺酰未取代或取代为苯环中的卤原子，-OH或C1-C3-烷基；G1代表苯氧基烷基，杂环氧基烷基-或杂环氧基烷基-哌嗪基；以及其药学上可接受的盐和溶剂合物。这些化合物可能对治疗和/或预防中枢神经系统疾病有用。
• [EN] INDOLEAMINE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES<br/>[FR] DÉRIVÉS INDOLÉAMINE UTILISÉS DANS LE TRAITEMENT DE MALADIES DU SYSTÈME NERVEUX CENTRAL
  申请人：ADAMED SP ZOO

  公开号：WO2013001499A1

  公开（公告）日：2013-01-03

  Indoleamine derivatives of formula (IA), wherein R1 represents benzyl unsubstituted or substituted with halogen atom, -OH, or C1-C3-alkyl; phenylsulphonyl unsubstituted or substituted in the phenyl ring with halogen atom, -OH or C1-C3-alkyl; G1 represents phenoxyalkyl, heteroaryloxyalkyl- or heterocyclyloxyalkyl-piperazine moiety; and pharmaceutically acceptable salts and solvates thereof. The compounds may be useful for the treatment and/or prevention of the central nervous system disorders.

  公式（IA）的吲哚胺衍生物，其中R1表示苯甲基未取代或取代有卤素原子，-OH或C1-C3-烷基；苯磺酰基未取代或在苯环中取代有卤素原子，-OH或C1-C3-烷基；G1表示苯氧基烷基，杂环氧基烷基-或杂环氧基烷基-哌嗪基；以及其药学上可接受的盐和溶解物。该化合物可用于治疗和/或预防中枢神经系统疾病。